Prise en charge thérapeutique des troubles cognitifs dans la Sclérose en plaques : Données et perspectives








télécharger 88.11 Kb.
titrePrise en charge thérapeutique des troubles cognitifs dans la Sclérose en plaques : Données et perspectives
page3/3
date de publication20.05.2017
taille88.11 Kb.
typeDocumentos
p.21-bal.com > comptabilité > Documentos
1   2   3
Rev Neurol (Paris),xx : xxx-xxx
BRUNNER R, SCHAEFER D, HESS K, PARZER P, RESCH F, SCHWAB S. (2005). Effect of corticosteroids on short-term and long-term memory. Neurology, 64: 335-7.
Chiaravalloti ND, Demaree H, Gaudino EA, DeLuca J. (2003). Can the repetition effect maximize learning in multiple sclerosis? Clin Rehabil, 17(1): 58-68.
COHEN JA, CUTTER GR, FISHER JS et al. (2002). Benefit of interferon beta-1-a on MFSC progression in secondary progressive MS. Neurology, 59(5): 679-87.
DECCO D, on behalf of the MS Rehab Study Group. (2004). Effects of donepezil in multiple sclerosis. Mult Scler, 10(Suppl. 2): S150
DIEPERINK E, WILLENBRING M, HO SB. (2000). Neuropsychiatric symptoms associated with hepatitis C and interferon alpha : A review. Am J Psychiatry, 157(6): 867-76.
EUROPEAN STUDY GROUP on Interferon beta-1b in secondary progressive MS. (1998). Placebon-controlled multicenter randomised trial of interferon beta 1b in treatment of secondary progressive multiple sclerosis. Lancet, 352(9139): 1491-7.
Fischer JS, PRIORE RL, JACOBS LD et al. (2000). Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol, 48: 885-92.
Geisler MW, SLIWINSKI M, COYLE PK, masur dm , DOSCHER C, krupp lb. (1996). The effects of amantadine and pemoline on cognitive functions in multiple sclerosis. Arch Neurol, 53: 185-8.
Geurts JJ, WOLSWIJK G, BO L, VAN DER VALK P, POLMAN CH, TROOST D, ARONICA E. (2003). Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain, 126 : 1755-66.
Goldstein G, Beers SR, Longmore S, McCue (1996). Efficacity of memory training: a technological extension and replication. Clin Neuropsychol, 10: 66-72.
Greene YM, TARIOT PN, WISHART H, COX C, HOLT CJ, SCHWID S, NOVIASKY J. (2000). A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol, 20: 350-6.
Groom AJ, SMITH T, TURSKI L. (2003). Multiple sclerosis and glutamate. Ann N Y Acad Sci, 993: 229-75.
Jonsson A, Korfitzen EM, Heltberg A, Ravnborg MH, Byskov-Ottosen E. (1993). Effects of neuropsychological treatment in patients with multiple sclerosis. Acta Neurol Scand, 88(6): 394-400.
Krupp LB, CHRISTODOULOU C, MELVILLE P, SCHERL WF, MAC ALLISTER WS, ELKINS LE. (2004). Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology, 63: 1579-85.
LEOCANI L, COMI E, ANNOVAZI P et al. (2007). Impaired short-term motor learning in multiple sclerosis: evidence from virtual reality. Neurorehabil Neural Repair, (in press).
LINCOLN NB, DENT A, HARDING J, WEYMAN N, NICHOLL C, BLUMHARDT LD, PLAYFORD ED. (2002). Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis. J Neurol Neurosurg Psychiatry, 72(1): 93-8.
MACALLISTER WS, BELMAN AL, MILAZZO M et al. (2005). Cognitive functioning in children and adolescents with multiple sclerosis. Neurology, 64(8): 1422-5.
MAINERO C, CARAMIA F, POZZILLI C et al. (2004). fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis. NeuroImage, 21: 858-67.
MONTALBAN X, RIO J. (2006). Interferons and cognition. J Neurol Sci, 245: 137-40.
MOOR AC, De VRIES HE, DE BOER AG, BREIMER DD. (1994). The blood-brain barrier and multiple sclerosis. Biochem Pharmacol, 47(10): 1717-24.
LLER UC, MONSCH AU, PLOHMAN AM et al. (2007). Cognitive rehabilitation of attentional functions in multiple sclerosis : a multi-center comparison of two training methods. Submitted for publication.
Oliveri RL, SIBILIA G, VALENTINO P, RUSSO C, ROMEO N, QUATTRONE A. (1998). Pulsed methylprodsolone induces a reversible impairment of memory in patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand, 97: 366-9.
Orgogozo JM, RIGAUD AS, STOFFLER A, MOBIUS HJ, FORETTE F. (2002). Efficacity and safety of memantine in patients with mild to moderate vascular dementia : a randomized, placebo-controlled trial (MMM 300). Stroke, 33(7): 1834-9.
PARRY AM, SCOTT RB, PALACE J, SMITH S, MATTHEWS PM. (2003). Potentially adaptive functional changes in cognitive processing for patient with multiple sclerosis and their acute modulation by rivastigmine. Brain, 126: 2750-60
PATZOLD T, SCHWENGELBECK M, OSSEGE LM, MALIN JP, SINDERN E. (2002). Cnahges in the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis. Acta Neurol Scand, 105 : 164-8.
Paul C, Bolton C. (1995). Inhibition of blood-brain barrier disruption in experimental allergic encephalomyelitis by short-termtherapy with dexamethasone or cyclosporine A. Int J Immunopharmacol, 17(6): 497-503.
Paul C, Bolton C. (1998). Antagonism of N-methyl-D-aspartate (NMDA) receptor activity with memantine limits blood-brain barrier (BBB) dysfunction and disease developpement during experimental allergic encephalomyelitis – EAE). J Neuro immunol, 90: 24.
Paul C, Bolton C. (2002). Modulation of blod-brain-barrier dysfunction and neurological deficits during acute expérimental allergic encephalomyelitis by the N-methyl-d-aspartate receptor antagonist memantine. JPET, 302: 50-57.
PENNER IK, KAPPOS L, RAUSCH M, OPWIS K, RADU EW. (2006). Therapy-induced plasticity of cognitive functions in MS patients : Insights from fMRI. J Physiol, 99: 455-462.
Pitt D, WERNER P, RAINE CS. (2000). Glutamate excitotoxicity in a model of multiple sclerosis. Nat Medicine, 6: 67-70.
Pliskin NH, HAMER DP, GOLDSTEIN DS, TOWLE VL, REDER AT, NORONHA A, ARNASON BG. (1996). Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology, 47(6): 1463-8.
Plohmann AM, Kappos L, Ammann W et al. (1998). Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 64(4): 455-62.
PORCEL J, MONTALBAN X. (2006). Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis. J Neurol Sci, 245: 177-181.
PRAKASH RS, SNOOK EM, ERICKSON KI, COLCOMBE SJ, VOSS MW, MOTL RW, KRAMER AF. (2007). Cardiorespiratory fitness: A predictor of cortical plasticity in multiple sclerosis. NeuroImage, 34: 1238-44.
RANJEVA JP, AUDOIN B, AU DUONG MV et al. (2006). Structural and functional surrogates of cognitive impairment at the very early stage of multiple sclerosis. J Neurol Sci, 245(1-2): 161-7.
Rao SM, LEO GJ, BERNARDIN L, UNVERZAGT F. (1991a). Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology, 41(5) : 685-691.
RAO SM, LEO GJ, ELLINGTON L, NAUERTZ T, BERNARDIN L, UNVERZAGT F. (1991b). Cognitive dysfuntion in multiple sclerosis. II. Impact on employment and social functioning. Neurology, 41(5): 692-6.
Rao SM. (1995). Neuropsychology of multiple sclerosis. Curr Opin Neurol, 8: 216-220.
Reisberg B, DOODY R, STOFFLER A, SCHMITT F, FERRIS S, MOBIUS HJ, Memantine Study Group. (2003). Memantine in moderate to severe Alzheimer’s disease. N Engl J Med, 348(14): 1333-41.
ROSSINI PM, PASQUALETTI P, POZZILLI C et al. (2001). Fatigue in progressive multiple sclerosis : results of a randomized, double-blind, placebo, crossover trial of oral 4-aminopyridine. Mult Scler, 7(6): 354-8.
Schmitt FA, CRAGAR D, ASHFORD JW, REISBERG B, FERRIS S, MOBIUS HJ, STOFFLER A. (2002). Measuring cognition in advanced Alzheimer’s disease for clinical trials. J Neural Transm, (62): 135-48.
SCHWID SR, GOODMAN AD, WEINSTEIN A, McDERMOTT MP, JOHNSON KP, for the Copaxone Study Group. (2007). Cognitive function in relapsing multiple sclerosis : Minimal changes in a 10-year clinical trial. J Neurol Sci, 255(1-2): 57-63.
SELBY MJ, LING N, WILLIAMS JM, DAWSON A. (1998). Interferon beta 1-b in verbal memory functioning of patients with relapsing-remitting multiple sclerosis. Percept Mot Skills, 86(3 Pt1): 1099-106.
Smith T, GROOM A, ZHU B, TURSKI L. (2000). Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Medicine, 6: 62-66.
SMITS RC, EMMEN HH, BERTESMANN FW, KULIG BM, VAN LOENEN AC, POLMAN CH. (1994). The effect of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology, 44(9): 1701-5.
Solari A, Motta A, Mendozzi L, Pucci E, Forni M, Mancardi G, Pozzilli C. (2004). Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-bind controlled trial. J Neurol Sc, 222: 99-104.
STAFFEN W, MAIR A, ZAUNER H et al. (2002). Cognitive function and fMRI in patients with multiple sclerosis: evidence for compensatory cortical activation during an attention task. Brain, 125(Pt6): 1275-82.
Takahashi JL, GIULIANI F, POWER C, IMAI Y, YONG VW. (2003). Interleukin 1beta promotes oligodendrocyte death through glutamate excitotoxicity. Ann Neurol, 53: 588-595.
WEINSTEIN A, SCHWID SI, SCHIFFER RB, McDERMOTT MP, GIANG DW, GOODMAN AD (1999). Neuropsychological status in multiple sclerosis afetr treatement with glatiramer. Arch Neurol, 56: 319-324.
Werner P, PITT D, RAINE CS. (2001). Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol, 50: 169-180.
Wilcock G, MOBIUS HJ, STOFFLER A, MMM 500 group. (2002). A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol, 17(6): 297-305.
ZEPHIR H, DE SEZE J, DUJARDIN K et al. (2005). One year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis. Mult Scler, 11: 360-363.



    Figure 1 PLAN EXPERIMENTAL




* Score PASAT 3s > 15 et < médiane / témoins selon âge, sexe, niveau scolaire.

Effets thérapeutiques de la Mémantine sur les troubles cognitifs des formes rémittentes de Sclérose en plaques : étude randomisée en double aveugle




1   2   3

similaire:

Prise en charge thérapeutique des troubles cognitifs dans la Sclérose en plaques : Données et perspectives iconRole de l’orthophoniste dans la sclerose laterale amyotrophique
«assurée, sereine» et de réaliser dans les meilleures conditions possibles cette prise en charge

Prise en charge thérapeutique des troubles cognitifs dans la Sclérose en plaques : Données et perspectives iconPrésentation du guide Ce guide méthodologique porte sur la prise...

Prise en charge thérapeutique des troubles cognitifs dans la Sclérose en plaques : Données et perspectives iconLa prise en charge des soins aupres de personne

Prise en charge thérapeutique des troubles cognitifs dans la Sclérose en plaques : Données et perspectives iconComment améliorer la prise en charge des femmes en cas de viol ?

Prise en charge thérapeutique des troubles cognitifs dans la Sclérose en plaques : Données et perspectives iconLe traitement nutritionnel des troubles cardio-vasculaires
«cœur lipidique». La sclérose (du grec skleros, dur) est la partie fibreuse qui, enchâssant le cœur lipidique, forme le pourtour...

Prise en charge thérapeutique des troubles cognitifs dans la Sclérose en plaques : Données et perspectives icon+ Prise en charge à l’hôtel ou à la gare.* +

Prise en charge thérapeutique des troubles cognitifs dans la Sclérose en plaques : Données et perspectives iconOrganisateur de temps de loisirs pour enfants et adolescents ayant...
«L'éducation ne se borne pas à l'enfance et à l'adolescence. L'enseignement ne se limite pas à l'école. Toute la vie, notre milieu...

Prise en charge thérapeutique des troubles cognitifs dans la Sclérose en plaques : Données et perspectives iconQuelle définition de l’éducation thérapeutique ?
«L'éducation thérapeutique s'inscrit dans le parcours de soins du patient. Elle a pour objectif de rendre le patient plus autonome...

Prise en charge thérapeutique des troubles cognitifs dans la Sclérose en plaques : Données et perspectives iconLe traitement des troubles concomitants : guide pour les conseillers
«double diagnostic» et «troubles jumelés»— soit considérée comme une discipline depuis deux décennies seulement, de nombreux cliniciens...

Prise en charge thérapeutique des troubles cognitifs dans la Sclérose en plaques : Données et perspectives iconProfil et prise en charge des patients diabétiques de type 2 traités...








Tous droits réservés. Copyright © 2016
contacts
p.21-bal.com